Effect of rosiglitazone on expression of CD36 in peripheral monocytes in patients with Type 2 diabetes

Abstract

Objective:To observe the expression of CD36 in peripheral monocytes in patients with Type 2 diabetes,and to study the influence of rosiglitazone on CD36 expression and the related the mechanism.Methods: The expression of CD36 in the peripheral monocytes of patients with Type 2 diabetes was measured by flow cytometry before and after rosiglitazone treatment;the correlation between monocytes CD36 expression and metabolic index was analyzed.Results: Flow cytometry showed that the mean fluorescence intensity(MFI) of monocyte CD36 in Type 2 diabetes was significantly higher than that in the healthy controls(745.9±281.3 vs 406.3±80.2,P0.01).CD36 MFI in patients with Type 2 diabetes atherosclerosis was significantly higher than that in patients with Type 2 diabetes non-atherosclerosis(878.2±296.1 vs 584.2±148.3,P0.01).Besides,we also found that CD36 expression,fasting blood glucose(FBG),post-prandial blood glucose(PBG),hemoglobin A1c(HbA1c),FIN,PIN,and HOMA-IR were all significantly decreased after rosiglitazone intervention compared with those before rosiglitazone intervetion and placebo group(P0.05 or P0.01).There was a positive correlation between monocyte CD36 expression with FBG(r=0.55,P0.05),HbA1c(r=0.62,P0.01),and HOMA-IR(r=0.64,P0.01);but the expression was not correlated with PBG,FIN,or PIN.Conclusion: The increased expression of CD36 in monocytes of patients with Type 2 diabetes may be one of the mechanisms for accelerated atherosclerosis in diabetic patients.Rosiglitazone can decrease CD36 expression in monocytes through effectively controlling the blood glucose and decreasing insulin resistance.